Agenus (AGEN) News Today $6.99 -0.07 (-0.99%) As of 02:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last weekJuly 14 at 8:59 AM | finance.yahoo.comAgenus (NASDAQ:AGEN) Share Price Crosses Above 200-Day Moving Average - Here's WhyJuly 12 at 4:58 AM | marketbeat.comAgenus unit, MiNK surges after peer-reviewed data for lead drugJuly 11 at 11:40 AM | seekingalpha.comZacks.com featured highlights Yext, Agenus and NCR VoyixJuly 10, 2025 | finance.yahoo.comWilliam Blair Reaffirms Their Hold Rating on Agenus (AGEN)July 9, 2025 | theglobeandmail.comAgenus’s Strategic Advancements and Promising Clinical Data Boost Investor ConfidenceJuly 8, 2025 | tipranks.comAgenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3July 7, 2025 | finance.yahoo.comAgenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3July 7, 2025 | businesswire.comAnalysts Set Agenus Inc. (NASDAQ:AGEN) Target Price at $14.00July 7, 2025 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by AnalystsJuly 4, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average - Should You Sell?July 2, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Share Price Crosses Above 200 Day Moving Average - Time to Sell?June 24, 2025 | marketbeat.com2 East Bay drugmaking sites sold to Indian manufacturerJune 20, 2025 | bizjournals.comAgenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell BiologyJune 17, 2025 | businesswire.comAgenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on StockJune 16, 2025 | insidermonkey.comAgenus Announces Virtual Annual Shareholders MeetingJune 10, 2025 | businesswire.comAgenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from AnalystsJune 9, 2025 | marketbeat.comAgenus Inc (AJ8.MU)June 8, 2025 | ca.finance.yahoo.comFY2027 Earnings Forecast for Agenus Issued By William BlairJune 6, 2025 | marketbeat.comHC Wainwright Forecasts Agenus' Q3 Earnings (NASDAQ:AGEN)June 6, 2025 | marketbeat.comBaird Lifts Agenus (AGEN) PT to $6, Maintains Neutral RatingJune 5, 2025 | msn.comH.C. Wainwright Upgrades Agenus (AGEN) Stock to BuyJune 4, 2025 | insidermonkey.comAnalyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangJune 4, 2025 | benzinga.comH.C. Wainwright Upgrades Agenus (AGEN) Stock to BuyJune 4, 2025 | msn.comAnalyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangJune 4, 2025 | benzinga.comAgenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the USJune 4, 2025 | tmcnet.comAgenus and Zydus sign agreements for botensilimab and balstilimabJune 4, 2025 | finance.yahoo.comAgenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. BairdJune 4, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Upgraded by HC Wainwright to Buy RatingJune 4, 2025 | marketbeat.comStrategic Collaboration Between Agenus and Zydus Lifesciences Boosts Financial Position and Product DevelopmentJune 4, 2025 | tipranks.comAgenus, Zydus Lifesciences Enter $141 Million DealJune 4, 2025 | marketwatch.comIndian shares set to open higher on hopes of easing global trade woesJune 4, 2025 | msn.comZynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reachJune 4, 2025 | finance.yahoo.comAgenus climbs on deal with India’s Zydus for cancer therapy BOT/BALJune 4, 2025 | msn.comJane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN)June 4, 2025 | marketbeat.comAgenus Stock Is Trading Higher Tuesday: What's Going On?June 3, 2025 | benzinga.comAgenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the USJune 3, 2025 | financialpost.comFAgenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal CancerMay 30, 2025 | finance.yahoo.comAgenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal CancerMay 30, 2025 | businesswire.comAgenus (NASDAQ:AGEN) Share Price Passes Above 200-Day Moving Average - Should You Sell?May 28, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.comMay 24, 2025 | marketbeat.comAgenus: Big On BOT/BAL As Cash Burn And Catalysts CollideMay 23, 2025 | seekingalpha.comWhat is B. Riley's Estimate for Agenus FY2025 Earnings?May 21, 2025 | marketbeat.comAgenus Inc. (NASDAQ:AGEN) Receives Average Recommendation of "Hold" from BrokeragesMay 17, 2025 | marketbeat.comAgenus says expanded MSS mCRC cohort data to be presented at ESMO GIMay 16, 2025 | finance.yahoo.comAgenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025May 15, 2025 | businesswire.comAgenus (NASDAQ:AGEN) Earns "Neutral" Rating from HC WainwrightMay 15, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Price Target Raised to $4.00 at Robert W. BairdMay 15, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Announces Earnings ResultsMay 14, 2025 | marketbeat.comAgenus appoints oncology veteran Dr. Goldberg as CDOMay 13, 2025 | uk.investing.com Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Media Mentions By Week AGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGEN News Sentiment▼0.531.01▲Average Medical News Sentiment AGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGEN Articles This Week▼86▲AGEN Articles Average Week Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Regulus Therapeutics News Myriad Genetics News Zenas BioPharma News Emergent Biosolutions News Rigel Pharmaceuticals News Lexicon Pharmaceuticals News XOMA Royalty News Crescent Biopharma News Vanda Pharmaceuticals News Verastem News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGEN) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
